FDA approves two products by Teva for asthma treatment

Teva Pharmaceutical announced that FDA has approved two products for adolescent and adult patients with asthma – AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder). Both treatments use Teva’s RespiClick, a breath-activated device. AirDuo is a fixed dose combination product containing the same active ingredients as Advair. ArmonAir, instead, is an inhaled corticosteroid containing the same active ingredient as Flovent. The products will become available in the US later this year, in three different doses. (Source Business Wire)